The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022.

Med-tech deal values the first seven months of the year are up more than 50% from last year. Meanwhile, M&As decreased almost 70% from the same time period in 2022.

The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022. In the first seven months of 2023, 778 deals were completed worth $105.39 billion, compared to 995 deals worth $105.9 billion in the same period last year, a decrease of 0.48% by value and a decrease of 21.8% by volume. The same timeframe in 2021 saw 1,240 deals valued at $107 billion, 1,228 deals worth $112.23 billion in 2020, and 963 deals totaling $93.39 billion in 2019.

Biopharmas raised $5.87 billion through 96 financings transactions in July 2023. The total amount raised is similar to the first six months of 2023 average of $5.48 billion per month, ranging from $3.74 billion in February to $8.02 billion in March of this year. Including July, the 2023 monthly average of money raised in all transactions is $5.46 billion.

Clinical data in the first half of 2023 is up 1.51% compared to the same time period last year. So far in 2023 BioWorld reported on 1,810 drugs in phase I-III, compared to 1,783 in the first half of 2022. The number of trial updates is down 13.6% from the 2,095 in 2021, but more than 2020’s 1,799 and 2019’s 1,477.

U.S. FDA drug approvals increased 19.18% compared to the first six months of last year, with June approvals up to 18 from the previous five months’ average of 14. Worldwide approvals are down 16.8% from the first half of 2022, but up 1.43% compared to the previous seven years’ average.

The biopharma industry experienced a notable decline in deal values and activity in June 2023, with a 48.51% decrease in deal values and a 43.62% decrease in the number of deals completed compared to the previous June. M&As, however, showed a remarkable 824.59% increase in value year over year in June, thanks to several billion-dollar transactions.